- News & Events
- Contact Us
Amgen Names David Beier Senior Vice President, Global Government Affairs
THOUSAND OAKS, Calif., Dec. 9 -- Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, today announced that David Beier has been named senior vice president, Global Government Affairs. Beier will be responsible for the operations of Amgen's Washington, D.C. office and the management of corporate regulatory and legislative issues.
Beier joins Amgen from the law firm of Hogan and Hartson in Washington, D.C. where he was a partner representing clients in the health care and technology fields, including pharmaceutical and biotechnology firms. He has an extensive government affairs and public policy background, and previously served as chief domestic policy advisor to the Vice President of the United States from 1998 to early 2001. He also held positions as vice president of government affairs and public policy for Genentech and staff counsel in the U.S. House of Representatives. Beier holds a J.D. from Albany Law School and a bachelor's degree from Colgate University.
"Drawing upon his strong government and industry experience, David will make a significant contribution to aligning Amgen's commercial interests with government affairs activities, as well as strengthening our presence in capitols at the federal, state and international level, " said George Morrow, Amgen's executive vice president of Global Commercial Operations.
Beier replaces Pete Teeley, who is assuming a new role as government affairs advisor for Amgen. Teeley also has an extensive government affairs background. He founded Amgen's Washington, D.C. office and has done an outstanding job leading Amgen's government affairs efforts over the past 10 years. Prior to joining Amgen, he held a variety of public positions in the 1980s, including serving as U.S. Ambassador to Canada and as Press Secretary and Assistant to the Vice President of the United States.
"Working to ensure that patients have access to our products and that our innovation in health care continues because we are able to receive the proper reimbursements for our therapies is a key task in achieving our corporate goals," Morrow said. "Amgen is fortunate to have these two high-caliber professionals leading a highly professional Washington staff in this effort."
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks Media, (805) 447-4587 Investors, (805) 447-1060